Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

Rury R Holman; Mary A Bethel; Juliana C N Chan; Jean-Louis Chiasson; Zoë Doran; Junbo Ge; Hertzel Gerstein; Yong Huo; John J McMurray; Lars Ryden; Winitha Liyanage; Stefan Schröder; Michal Tendera; Michael J Theodorakis; Jaakko Tuomilehto; Wenying Yang; Dayi Hu; Changyu Pan; ACE Study Group

doi:10.1016/j.ahj.2014.03.021

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

Am Heart J. 2014 Jul;168(1):23-9.e2. doi: 10.1016/j.ahj.2014.03.021. Epub 2014 Apr 5.

Authors

Rury R Holman¹, Mary A Bethel², Juliana C N Chan³, Jean-Louis Chiasson⁴, Zoë Doran², Junbo Ge⁵, Hertzel Gerstein⁶, Yong Huo⁷, John J McMurray⁸, Lars Ryden⁹, Winitha Liyanage², Stefan Schröder¹⁰, Michal Tendera¹¹, Michael J Theodorakis², Jaakko Tuomilehto¹², Wenying Yang¹³, Dayi Hu¹⁴, Changyu Pan¹⁵; ACE Study Group

Collaborators

ACE Study Group:
R R Holman, C Y Pan, D Y Hu, J Chan, J-L Chiasson, Z Doran, J Ge, H Gerstein, Y Huo, Z Lang, J McMurray, L Ryden, S Schröder, M Tendera, J Tuomilehto, W Yang, J Rouleau, J Collier, S Pocock, E Standl, K Swedberg, J Weng, D Zhao, D Wang, M Petrie, E Connelly, P Jhund, M MacDonald, R Myles, N Sattar, M Fisher, J Petrie, Y Sun, Y Wei, W Xu, N Groves, W Liyanage, J Tang, M J Theodorakis, J Bi, H Feng, R Hu, P Liu, M Wei, X Wei, X Yang, J Yin, J Zhou, L Deng, D Hu, Q Hua, T Hu, H Li, H Li, J Lu, C Ma, X Ma, L Pi, L Shi, B Wang, M Wang, G Wei, M Yang, W Yang, L Zhang, S Zhang, Y Zhou, H Lei, R Liao, X Mei, Q She, J Tan, M Xia, L Chen, X Pu, Y Wang, Q Xie, S Xiong, C Chen, J Chen, Y Dong, Z Li, C Wu, S Zhou, Y Yuan, W Zhou, R Kuang, J Wei, Z Zhao, G Zhong, L Wu, H Fang, H Li, L Kong, G Liu, Y Hao, C Wang, X Li, L Wang, P Dong, H Liu, X Liu, S Zhang, Y Zhao, J Chan, Risa Ozaki, Y Gu, Y Liao, X Su, D Wang, H Wang, B Yang, Y Guo, T Yang, Y Han, X Lin, R Zhao, R Bian, Y Guo, H Zhang, B Hasimu, H Jin, P Liu, K Lv, Y Tao, C Xu, B Xu, Z Yang, J Yu, G Zhang, L Hong, L Hu, J Li, B Liu, P Yang, P Han, Y Jin, L Li, H Lin, J Liu, Z Li, G Wang, S Zhang, H Luan, M Song, L Xue, J Feng, F Gao, Y Hua, J Ye, Z Yuan, Z Hou, X Li, W Qi, G Su, Y Wang, S Zhang, B Wang, J Ge, X Guo, H Gong, S Gu, B He, Y Jiang, H Jin, Y Li, Q Liu, G Lu, J Ma, Y Qin, S Wu, Y Xu, X Chen, J Tang, J Wang, D Liu, X Chen, J Tao, Y Yan, T Zhang, D Li, X Du, X Guo, T Jiang, T Li, Z Li, J Lin, C Lu, S Zhao, S Zheng, K Li, Q Qui, B Tang, J Zhou, G Zhang, T Guo, H Zhang, F Shen, G Fu

Affiliations

¹ Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom. Electronic address: rury.holman@dtu.ox.ac.uk.
² Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
³ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
⁴ CRCHUM, Department of Medicine, University of Montreal, Montreal, Canada.
⁵ Zhongshan Hospital, Fudan University, Shanghai, China.
⁶ Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
⁷ Department of Cardiology, Peking University First Hospital, Beijing, China.
⁸ Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
⁹ Cardiology Unit, Karolinska University Hospital Solna, Stockholm, Sweden.
¹⁰ Bayer Healthcare, Bayer Pharma AG, Berlin, Germany.
¹¹ 3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland.
¹² Centre for Vascular Prevention, Danube-University Krems, Krems, Austria; Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; King Abdulaziz University, Jeddah, Saudi Arabia.
¹³ China-Japan Friendship Hospital, Beijing, China.
¹⁴ People's Hospital of Peking University, Beijing, China.
¹⁵ Department of Endocrinology, People's Liberation Army General Hospital, Beijing, China.

PMID: 24952856
DOI: 10.1016/j.ahj.2014.03.021

Abstract

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.

Publication types

Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Acarbose / therapeutic use*
Blood Glucose / drug effects
Blood Glucose / metabolism*
Coronary Disease / blood
Coronary Disease / complications
Coronary Disease / prevention & control*
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / prevention & control*
Disease Progression
Double-Blind Method
Follow-Up Studies
Glucose Intolerance / blood
Glucose Intolerance / complications
Glucose Intolerance / drug therapy*
Humans
Hypoglycemic Agents / therapeutic use
Prospective Studies
Secondary Prevention / methods*
Treatment Outcome

Substances

Blood Glucose
Hypoglycemic Agents
Acarbose